Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2021

View Archived Issues

TRIM47 targeting shows potential for treating breast cancer refractory to endocrine therapy

Gilead describes new antiviral nucleoside analogues

New GCN2 inhibitors identified at Black Belt TX

As targeted options expand, making the best match, and the most matches

Targeting GCN2 or elevating tRNAGly levels may be useful in Charcot-Marie-Tooth disease

IP6K regulates circulating phosphate and intracellular ATP in mammals

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents antibodies binding IL-4RA

Single-cell transcriptome of human melanocytes during development, aging and malignancy

Discovery of novel compounds with potent activity against resistant bacteria

TSHA-104 AAV9 gene-replacement therapy for Leigh syndrome shows promising results

MEGs and MBK-2 clusters regulate P granule dynamics and coarsening

Rasarfin, a dual Ras and ARF6 inhibitor with promising antitumor activity

NIDA agrees to screen Initiator Pharma's preclinical assets for anti-addictive properties

Researchers report improved DHODH inhibitors, anti-coronavirus activity

Kissei Pharmaceutical discovers EGLN1 inhibitors

SpectrumX reports in vitro neutralizing efficacy of SPC-069 against SARS-CoV-2 variants

ETX-0462 is a potent antibiotic against Pseudomonas aeruginosa

BET protein inhibition can reverse CAR T-cell exhaustion

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.